

[ Thu, Apr 08th 2021
] - WOPRAI
[ Thu, Apr 08th 2021
] - WOPRAI
[ Thu, Apr 08th 2021
] - WOPRAI
[ Thu, Apr 08th 2021
] - WOPRAI
[ Thu, Apr 08th 2021
] - WOPRAI

[ Wed, Apr 07th 2021
] - WOPRAI
[ Wed, Apr 07th 2021
] - WOPRAI
[ Wed, Apr 07th 2021
] - WOPRAI
[ Wed, Apr 07th 2021
] - WOPRAI
[ Wed, Apr 07th 2021
] - WOPRAI
[ Wed, Apr 07th 2021
] - WOPRAI
[ Wed, Apr 07th 2021
] - WOPRAI
[ Wed, Apr 07th 2021
] - WOPRAI
[ Wed, Apr 07th 2021
] - WOPRAI
[ Wed, Apr 07th 2021
] - WOPRAI
[ Wed, Apr 07th 2021
] - WOPRAI
[ Wed, Apr 07th 2021
] - WOPRAI
[ Wed, Apr 07th 2021
] - WOPRAI
[ Wed, Apr 07th 2021
] - WOPRAI
[ Wed, Apr 07th 2021
] - WOPRAI
[ Wed, Apr 07th 2021
] - WOPRAI
[ Wed, Apr 07th 2021
] - WOPRAI
[ Wed, Apr 07th 2021
] - WOPRAI
Andrew Fein Downgraded (ACAD) to Hold and Decreased Target to $18 on, Apr 7th, 2021
Andrew Fein of HC Wainwright & Co., Downgraded "ACADIA Pharmaceuticals Inc." (ACAD) to Hold and Decreased Target from $43 to $18 on, Apr 7th, 2021.
Andrew has made no other calls on ACAD in the last 4 months.
There are 11 other peers that have a rating on ACAD. Out of the 11 peers that are also analyzing ACAD, 8 agree with Andrew's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Chris Howerton of "Jefferies" Downgraded from Strong Buy to Hold and Decreased Target to $21 on, Tuesday, April 6th, 2021
- Salveen Richter of "Goldman Sachs" Downgraded from Strong Buy to Hold and Decreased Target to $25 on, Tuesday, April 6th, 2021
- Sumant Kulkarni of "Canaccord Genuity" Downgraded from Strong Buy to Hold and Decreased Target to $26 on, Tuesday, April 6th, 2021
- Vamil Divan of "Mizuho" Downgraded from Strong Buy to Hold and Held Target at $25 on, Tuesday, April 6th, 2021
- Tazeen Ahmad of "B of A Securities" Downgraded from Strong Buy to Hold on, Wednesday, March 10th, 2021
- Neena Bitritto-Garg of "Citigroup" Downgraded from Strong Buy to Hold and Decreased Target to $35 on, Tuesday, March 9th, 2021
- Paul Matteis of "Stifel" Downgraded from Strong Buy to Hold and Decreased Target to $27 on, Tuesday, March 9th, 2021
- Yatin Suneja of "Guggenheim" Downgraded from Strong Buy to Hold on, Tuesday, March 9th, 2021
These are the ratings of the 3 analyists that currently disagree with Andrew
- Jeffrey Hung of "Morgan Stanley" Maintained at Buy with Decreased Target to $28 on, Tuesday, April 6th, 2021
- Joseph Stringer of "Needham" Maintained at Strong Buy with Decreased Target to $30 on, Monday, April 5th, 2021
- Danielle Brill of "Raymond James" Downgraded from Strong Buy to Buy and Decreased Target to $35 on, Tuesday, March 9th, 2021
Contributing Sources